

Source

Anti-Cetuximab Antibody (12B1E9) (CEB-Y29c) is a monoclonal antibody recombinantly expressed from human 293 cells (HEK293). The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab ADA.

Isotype

Mouse IgG1/kappa

Specificity

Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.

Purity

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Endotoxin

Less than 1.0 EU per µg by the LAL method.

Formulation

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.


SDS-PAGE



Anti-Cetuximab Antibody (12B1E9) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-Elisa

SEC-MALS




The purity of Anti-Cetuximab Antibody (12B1E9) (Cat. No. CEB-Y29c) is more than 90% and the molecular weight of this protein is around 130-160 kDa verified by SEC-MALS.

Report

Anti-Cetuximab Antibody (12B1E9) (recommended for PK/PD, MALS verified)

Catalog # CEB-Y29c





Immobilized Cetuximab at 1 μ g/mL (100 μ L/well) can bind Anti-Cetuximab Antibody (12B1E9) (Cat. No. CEB-Y29c) with a linear range of 0.2-1.6 ng/mL (QC tested).

Background

Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.

Clinical and Translational Updates

Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.